ALG6

Across TCGA pan-cancer cohorts, ALG6 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated ALG6 data layer compared with 25 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher ALG6 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated ALG6 expression acts as an unfavorable survival marker, although some lineages such as LUAD and LSCC show a favorable association.

LUAD, LSCC, and UCEC are the cancer types where ALG6 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	III,IV	0.789	0.331	.013	7	view →
LSCC	OS	Quartile	III,IV	0.808	0.432	.026	4	view →
UCEC	DFS	Tertile	All	0.817	0.969	.048	4	view →
GBM	OS	Tertile	All	0.555	0.265	.013	4	view →
PDAC	OS	Tertile	All	0.332	0.503	.037	2	view →
HNSC	OS	Quartile	All	0.808	0.576	.024	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

ALG6–LUAD (DFS)

Open the LUAD breakdown →